Seoul City-Novartis-Cardiovascular Intervention Society Join Hands for Vascular Health of Seoul Citizens

Seoul Metropolitan Government, Korea Novartis, and the Korean Society of Cardiovascular Interventions announced on the 26th that they signed a business agreement on the 25th to prevent and manage dyslipidemia among Seoul citizens.

Seoul Metropolitan Government, Novartis Korea, and the Korean Society of Cardiovascular Interventions announced on the 26th that they signed a business agreement on the 25th to prevent and manage dyslipidemia among Seoul citizens. At the signing ceremony, Byungjae Yoo, CEO of Novartis Korea, Cheolwon Kang, Deputy Mayor for Political Affairs of Seoul, and Donghoon Choi, President of the Korean Society of Cardiovascular Interventions (from left), posed for a commemorative photo.
[Photo by Novartis Korea]

According to this agreement, the three organizations plan to promote various cooperative projects in the future, including ▲vascular health management education and awareness campaigns to prevent dyslipidemia among Seoul citizens ▲early detection projects for dyslipidemia patients linked with cardiovascular and metabolic syndrome programs ▲treatment, comprehensive health management, and improvement of continuous care levels for high-risk dyslipidemia patients.

Heart disease is the leading cause of death worldwide and the second leading cause of death in South Korea, with more than 34 people dying every minute and over 18 million annually from heart disease globally. The mortality rate from heart disease in Seoul was 24.9 per 100,000 people in 2021, ranking sixth among the 17 metropolitan cities and provinces nationwide. Dyslipidemia is a significant risk factor causing cardiovascular diseases such as angina, myocardial infarction, and stroke (cerebral infarction), and the number of patients has been steadily increasing. Therefore, there has been a continuous call for active policies to prevent and manage dyslipidemia.

The tripartite business agreement ceremony to establish a dyslipidemia prevention and management system for Seoul citizens was held on the 25th at Seoul City Hall, attended by Kang Cheol-won, Deputy Mayor for Political Affairs of Seoul, Choi Dong-hoon, President and executives of the Korean Society of Cardiovascular Interventions, and Yoo Byung-jae, CEO of Korea Novartis.

Park Yu-mi, Director of the Seoul Metropolitan Government’s Citizen Health Bureau, said, “Seoul operates a metabolic syndrome management program that anyone aged 20 to 64 can participate in to prevent and manage cardiovascular diseases.” She added, “With this business agreement as an opportunity, we will strengthen cardiovascular health management for Seoul citizens at all stages, from preventing dyslipidemia, which causes cardiovascular diseases, to treating and continuously managing high-risk patients.”

Choi Dong-hoon, President of the Korean Society of Cardiovascular Interventions, stated, “South Korea has world-class medical personnel and infrastructure and is striving to establish a national-level response system for cardiovascular disease treatment.” He continued, “Starting with this agreement, the Society will build cooperative systems with local governments and industry to detect dyslipidemia patients early as a major risk factor for cardiovascular diseases in clinical settings and to continuously treat and manage them.”

Yoo Byung-jae, CEO of Korea Novartis, also said, “Low-density lipoprotein cholesterol (LDL-C) is a direct cause of cardiovascular disease, and maintaining its level low is important for recurrence prevention and management. However, public awareness and management measures have been insufficient.” He added, “Korea Novartis will actively cooperate to build a management system that informs Seoul citizens about the risks of bad cholesterol and provides continuous cholesterol monitoring and early treatment opportunities for high-risk dyslipidemia patients.”

This content was produced with the assistance of AI translation services.